Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials

Lantern Pharma  a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo M.D., M.Sc., MBA, as Vice President of Clinical Development, and several additional team members. The expansion of the clinical development team will continue to advance the Harmonic trial, a Phase 2 trial for never smokers with NSCLC, as well as the upcoming first-in-human Phase 1 clinical trials for Lantern’s drug candidates LP-184 and LP-284, which are both anticipated to launch in mid-2023.

Recommended AI News: LZG International, Inc. (FatBrain AI) Announces Plans to Uplist to OTCQB Venture Market

“We are looking forward to the many contributions that Dr. Ewesuedo and our expanded clinical development team will bring to Lantern and our clinical programs,” said Panna Sharma, Lantern’s President and CEO. “They are joining Lantern at a pivotal period in our company’s growth as we advance our drug candidates into and through clinical trials. I am confident in the decades of proven experience of our new team members and their ability to progress Lantern’s drug candidates to improve the lives of cancer patients,” continued Sharma.

Dr. Ewesuedo has over 20 years of experience in preclinical, early, and late phase drug development including roles in clinical development leadership at AstraZeneca, Genzyme/Sanofi, Pfizer, Tesaro/GlaxoSmithKline, and Kymera. His leadership and experience have led to the development of several drugs including the successful filings for Trazimera™ (trastuzumab), Nyvepria™ (pegfilgrastim), and Zirabev (bevacizumab), while he was at Pfizer. In addition to his industry experience, he also served as a clinical research faculty member at The Ohio State University from 2000-2005. He holds an M.D. from the University of Ibadan, College of Medicine, Ibadan, Nigeria, a M.Sc. in Pharmacology from Ahmadu Bello University, Zaria, Nigeria, and an MBA from St. Mary’s University, Greehey Business School, San Antonio, TX. Dr. Ewesuedo completed his subspecialties training in Hematology and Pediatric Oncology, and Clinical Pharmacology and Pharmacogenomics, at the University of Chicago.

Recommended AI: Microsoft 365 Security Features Protect Business Data from Evolving Threats

Lantern has also recently appointed Ernest Kitt as Head of Clinical Operations. Mr. Kitt has over 20 years of experience in oncology drug development and clinical operations with proven success in bringing drugs to market. He has held clinical oncology leadership positions at companies including Amgen/Onyx, Aptose, and Biosplice. Other additions to the clinical development team include Annum Zhara as a Senior Clinical Trial Project Manager and Brianna MacCrory as a Clinical Trial Navigator.

Recommended AI News: Prisma Cloud Delivers Context-Aware Software Composition Analysis to Secure Deployment of Open Source Software

[To share your insights with us, please write to sghosh@martechseries.com]